Article Text

Download PDFPDF

Correction: Anti-PD-L1 (atezolizumab) as an immune primer and concurrently with extended-field chemoradiotherapy for node-positive locally advanced cervical cancer
Free

Statistics from Altmetric.com

Mayadev J, Zamarin D, Deng W, et al. Anti-PD-L1 (atezolizumab) as an immune primer and concurrently with extended-field chemoradiotherapy for node-positive locally advanced cervical cancer. Int J Gynecol Cancer 2019;30:701–4. doi: 10.1136/ijgc-2019-001012

For this article, the authors noticed that their updated funding statement was incorrect. The correct funding statement is ‘This study was supported by National Institute of Health grants to NRG Oncology (1U10 CA180822) and NRG Operations (U10CA180868).’

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.